Attana and 19 Plus AB (Testmottagningen.se by Zample) sign collaboration agreement of marketing and sales of Attana individual immunity profiles
Attana can today announce that the company has signed a collaboration agreement with 19 Plus AB for the marketing and sales of Attana individual immunity profiles for Covid 19.
Testmottagingen.se by Zample (a brand name owned by 19 Plus AB) started operations in connection with the pandemic outbreak to meet the demand for covid test for travelling. The operations have thereafter expanded to include different health tests which will soon include individual immunity profiles by Attana with respect to wuhan and omicron mutations.
The ambition is to by operational with the individual immunity profiles within three weeks to meet the demand of test prior to the Swedish “sportlov” (Swedish winter sports vacation from schools). The goal is to offer individuals immunity profiles before and after the sportlov and to combine with pcr-test, enabling for induvials to make their own estimate of their immunity and potential exposure to covid during the vacation.
Following the sportlov 19 Plus AB and Attana AB will evaluate and with time include individual immunity profiles for more pathogens in agreement with the long-term vision previously described by Attana.
Attana CEO, Teodor Aastrup comments:
” Since we introduced the concept of individual immunity profiling we have received several request from individuals who has wanted their own immunity profile. However, previously we have not had the capacity to offer that. Meanwhile several of our international customers has used Attana technology in similar research, strengthening our belief in the concept of individual immunity profiles. In Testmottagningen.se by Zample we have found a partner with the right infrastructure to meet the demand. I am eager to see the outcome of this offering”
19 Plus, Testmottagningen.se by Zamples CEO, Alexander Halldin add:
” We have had an increased demand from our customers to include other health tests, such as allergy, intolerance and immunity testing. Individual immunity test from Attana fits perfect to meet this demand for the coming sportlov.”
For more information, please contact:
Teodor Aastrup, CEO
teodor.aastrup@attana.com
+46 (0)8 674 57 00
The Board of directors for Attana consider that the information in this press release is not likely to have a significant effect on the share price but is of general interest for the shareholders and hence should be communicated.
About Attana
Attana was founded in 2002 with the vision of in vitro characterization of molecular interactions mimicking in vivo conditions. Since then, Attana has developed proprietary label free biosensors for biochemical, crude, sera, and cell-based assays and the Attana Virus Analytics (AVA) platform, a proprietary in vitro diagnostics (IVD) tool. Attana products and research services are used by Big Pharma, biotech companies and academic institutions within the life sciences. To learn more about our latest services and products, please visit www.attana.com or contact sales@attana.com
Tags: